GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dong-A Socio Holdings Co Ltd (XKRX:000640) » Definitions » Debt-to-EBITDA

Dong-A Socio Holdings Co (XKRX:000640) Debt-to-EBITDA : 7.23 (As of Sep. 2024)


View and export this data going back to 1970. Start your Free Trial

What is Dong-A Socio Holdings Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Dong-A Socio Holdings Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ₩441,472 Mil. Dong-A Socio Holdings Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ₩290,291 Mil. Dong-A Socio Holdings Co's annualized EBITDA for the quarter that ended in Sep. 2024 was ₩101,167 Mil. Dong-A Socio Holdings Co's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was 7.23.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Dong-A Socio Holdings Co's Debt-to-EBITDA or its related term are showing as below:

XKRX:000640' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.71   Med: 4.09   Max: 7.68
Current: 7.68

During the past 13 years, the highest Debt-to-EBITDA Ratio of Dong-A Socio Holdings Co was 7.68. The lowest was -2.71. And the median was 4.09.

XKRX:000640's Debt-to-EBITDA is ranked worse than
87.65% of 656 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs XKRX:000640: 7.68

Dong-A Socio Holdings Co Debt-to-EBITDA Historical Data

The historical data trend for Dong-A Socio Holdings Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dong-A Socio Holdings Co Debt-to-EBITDA Chart

Dong-A Socio Holdings Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.80 2.07 3.92 5.35 4.25

Dong-A Socio Holdings Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.13 5.89 9.50 8.25 7.23

Competitive Comparison of Dong-A Socio Holdings Co's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Dong-A Socio Holdings Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dong-A Socio Holdings Co's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dong-A Socio Holdings Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Dong-A Socio Holdings Co's Debt-to-EBITDA falls into.



Dong-A Socio Holdings Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Dong-A Socio Holdings Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(420088.777 + 271792.893) / 162650.357
=4.25

Dong-A Socio Holdings Co's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(441472.033 + 290291.232) / 101166.552
=7.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


Dong-A Socio Holdings Co  (XKRX:000640) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Dong-A Socio Holdings Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Dong-A Socio Holdings Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Dong-A Socio Holdings Co Business Description

Traded in Other Exchanges
N/A
Address
252 Yongdu-Dong, Dongdaemun-Gu, Seoul, KOR
Dong-A Socio Holdings Co Ltd is a pharmaceutical company. The company is engaged in the development of biomedicines and innovative drugs, and to expand businesses from pharmaceuticals to medical services and new businesses.

Dong-A Socio Holdings Co Headlines

No Headlines